Darbepoetin alfa is used in the treatment of anemia due to chronic kidney disease and anemia due to chemotherapy.
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Avoid consumption of alcohol while taking Embardia Injection as it may increase dizziness and sleepiness.
Embardia 40mcg/0.4ml Injection should be used with caution in pregnant women. If you are pregnant, think you may be pregnant, or are planning for a baby, consult your doctor before receiving it.
Embardia 40mcg/0.4ml Injection is not recommended for use in breastfeeding women because it is not known if it is excreted in breast milk. Consult your doctor before receiving it.
Embardia 40mcg/0.4ml Injection should not affect the ability to drive or use machines.
In patients with chronic kidney failure, your doctor will adjust the correct dose and duration of Embardia 40mcg/0.4ml Injection management depending on your age, body weight, and disease condition. Consult your doctor before receiving Embardia 40mcg/0.4ml Injection.
Embardia 40mcg/0.4ml Injection should be used with caution in patients with liver disease and hepatitis C. Consult your doctor before receiving Embardia 40mcg/0.4ml Injection.
DARBEPOETIN ALFA
Treatment of Anaemia (in cancer and chronic kidney disease)
Embardia (Darbepoetin alfa) is indicated for the treatment of anemia due to:
Darbepoetin alfa is an erythropoiesis-stimulating agent (ESA). It is produced through recombinant DNA technology in Chinese Hamster Ovary (CHO) cells. It stimulates the production of red blood cells by acting on erythroid progenitor cells, similar to erythropoietin. Darbepoetin alfa differs from recombinant human erythropoietin by having five N-linked oligosaccharide chains (compared to three), leading to an extended half-life and prolonged activity.
Chronic Renal Failure (Adult Patients):
Chronic Renal Failure (Pediatric Patients ≥1 year):
Chemotherapy-Induced Anemia (Adult Cancer Patients):